



RADIATION INDUCED TOXICITY OF ABDOMINAL ORGANS

PROF. DR. S N SENAPATI

PRESIDENT ELECT

AROI

PROFESSOR

DEPT. OF RADIATION ONCOLOGY

AH POSTGRADUATE INSTITUTE OF CANCER, CUTTACK



LEARNING OBJECTIVES

- ◆ **WHAT??? ;- TOXICITY**
- ◆ **HOW???:- MECHANISM**
- ◆ **WHO??? :- ORGANS AFFECTED**
- ◆ **WHEN??? :- FACTORS GOVERNS**
- ◆ **WHERE???:-ORGAN CONCERNED**
- ◆ **STRATEGIES TO PREVENT???**

10 Bollywood Stars Who Hate Alcohol

WHAT ?



ATE RADIATION TO ACHIEVE BETTER
THERAPEUTIC RATIO
Signature
NORMAL TISSUE

REVIEW SERIES: MYOXSIA AND INFLAMMATION
Series Editor: Dr. Collette R. R. R. R.
Reducing radiation-induced gastrointestinal toxicity —
the role of the PHD/HIF axis
ARONIS AL, GROSS S and JAMES L. GIBSON
Department of Radiation Oncology, University of California, San Francisco, California, USA

Prof. Dr. S N Senapati

5/16/2024





HOW?

APOPTOSIS

NECROPTOSIS

SENESCENCE


IMMUNOGENIC
CELL DEATH

FERROPTOSIS

LOW DOSES TEND TO INDUCE APOPTOSIS, WHILE HIGH DOSES ARE MORE INCLINED TO INDUCE CELL NECROSIS. EXPERIMENTAL RESULTS SHOW THAT ACTIVE CASPASE-8 INDUCES CELL APOPTOSIS UNDER LOW-DOSE RADIATION AND INHIBITS NECROSIS BY CLEAVING RIP. HOWEVER, DECREASED CASPASE-8 ACTIVITY PROMPTS THE FORMATION OF INTRACELLULAR RIP1/RIP3 COMPLEX TO MEDIATE NECROPTOSIS IN TUMOR CELLS (Zhou et al. 2021). (Przybyszewski et al. 2008).

EFFECT OF RADIATION

Radiation damages DNA and cellular components in tumor and bystander cells, indirectly via free radicals generated from water molecules (A, 70%) or from direct ionization (B, 30%)



MITOTIC CELL DEATH

PROLIFERATIVE DEATH

DNA DAMAGE

Mitosis

- Radioresistant
- Moderately radiosensitive
- Highly radiosensitive

2nd gap
(cell
structurally
prepares to
divide)

INTERPHASE

APOPTOSIS


DNA synthesis

1st gap
(RNA and
roteins are
produced)

G0


Cell cycle
arrest

APOPTOSIS



INTRINSIC PATHWAY OF APOPTOSIS

MITOCHONDRIA/ENDOPLASMIC RETICULUM




APOPTOTIC PATHWAY

2/20/08


MORPHOLOGY OF APOPTOSIS

scribble

IN APOPTOSIS



Good





NK module plays an important role in apoptosis, inflammation

Radiation may sequentially activate the Rho family and SPAK/JNK pathways by oxidizing the sphingomyelin on the plasma membrane into ceramide and other multiple pathways to regulate the occurrence of apoptosis in tumor cells. (Przybyszewski et al. 2008).


RADIATION TRIGGER OXIDATIVE STRESS, PEROXIDATION OF INTRACELLULAR MACROMOLECULES, OVERPRODUCTION OF ROS AND THE CONCENTRATION OF CALCIUM IONS INCREASES WHICH ACTIVATE AND PROMOTE THE MPT-DRIVEN NECROSIS (GALLUZZI ET AL. 2014). Parthanatos occurs with hyperactivation of PAPR1 when radiation inflicts excessive DNA damage or provokes intracellular production of iNOS and NO in tumor cells (Zhou et al. 2021).

MPT (MITOCHONDRIAL PERMEABILITY TRANSITION PORE COMPLEX" (PTPC





AT THE ONSET OF SENESENCE, ALTHOUGH METABOLISM IS STILL ONGOING, CELLS WILL PERMANENTLY LOSE THEIR ABILITY TO PROLIFERATE, BE IRREVERSIBLY BLOCKED IN THE STATE OF G1 PHASE, AND EVENTUALLY DIE (REGULSKI 2017). IS A FORM OF PROLIFERATION CELL DEATH TRIGGERED BY RADIATION. ACTIVATION OF P53 FACILITATES CELL SURVIVAL THROUGH GROWTH ARREST AND DNA DAMAGE REPAIR. ACCORDING TO THE EXTENT AND TYPE OF DAMAGE, HOWEVER, P53 PROMOTES THE SENESENCE OF TUMOR CELLS AFTER RADIOTHERAPY, OFTEN ACCOMPANIED BY P21 EXPRESSION. WHEN P53 SIGNALING IS IMPAIRED, RADIATION-INDUCED SENESENCE SEEMS TO BE DIMINISHED.

Site of Cancer	Organs of concern
CA GEJ/ CA Stomach	
CA Pancrease	
Paraaortic irradiation (Cervix/ Lymphoma/ Testicular Tumours)	
CA Gallbladder	
HCC/ Cholangiocarcinoma	
Retroperitoneal Sarcoma	
RCC/ Wilm's Tumour	

ACUTE:-I,II,III,IV
LATE:-TELANGIECTASIA,OEDEMA,FIBROSIS

SKIN

DIABETES,
LIPASE & AMYLASE
DEF.

PANCREAS

KIDNEY

NEPHRITIS,RENAL
FAILURE

BOWEL


RADIATION ENTERITIS
INT OBSTRUCTION

STOMACH

GASTRITIS,ULC
ERATION,CHRO
NIC ATROPHIC
GASTRITIS,INTE
STINAL
METAPLASIA

LIVER

- VENO OCCLUSIVE DISEASES
- DECLINE IN HEPATIC FUNCTION
- WORSENING CHILD-PUGH SCORE
- INCREASING ASCITES
- HEPATITIS,CIRRHOSIS





ORGAN OF CONCERN



ORGAN (MOSTLY MIXED TYPE- PARALLEL & SERIAL, ACCORDING TO FSUS)	ACUTE SYMPTOMS	CHRONIC SYMPTOMS

FACTORS GOVERNS

MEDICAL COMORBIDITIES

VASCULAR DISEASES

CONNECTIVE TISSUE DISEASE

INFLAMMATORY BOWEL DISEASE

HIV

GENETIC SUSCEPTIBILITY

SINGLE NUCLEOTIDE

POLYMORPHISM

ATAXIA TELANGECTASIA

HOST

ORGAN

- ACUTE Vs LATE REACTING TISSUE
- SERIAL Vs PARALLEL
- TOLERANCE

RT/CT
RT

COMBINED MODALITY
THERAPIES
SURGERY (PRIOR TO RT)
CHEMOTHERAPY,
PARTICULARLY
CONCURRENT (EG-5-FU)

DOSE
VOLUME

- TREATMENT VOLUME
- TOTAL DOSE
- FRACTIONATION DOSE
- SCHEDULE

TECHNOLOGY

IMRT
IGRT
VMAT

CASARETTS CLASSIFICATION OF RADIOSENSITIVITY

Cell Type	Properties	Examples	Sensitivity ^a

THE TIME INTERVAL BETWEEN THE IRRADIATION AND THE CRISIS DEPENDS ON
LIFE SPAN OF VEGETATIVE INTERMITOTIC CELL
PERCENTAGE OF SURVIVING FUNCTIONAL CELLS

^aSensitivity decreases for each successive group

^bIntermediate in sensitivity between groups II and III

PHILOSOPHY BEHIND THE COMPLICATIONS IN RELATION TO CELL

RADIOSENSITIVITY(cowdery etal)

ORDER OF RADIOSENSITIVITY

LOW



FIXED POSTMITOTIC CELLS



REVERSIBLE POSTMITOTIC CELLS

HISTOHEMATOPOIETIC
MICROCELLS

POTENTIAL CONNECTIVE
TISSUE CELLS

DIFFERENTIATING INTERMITOTIC CELLS


HIGH




VEGETATIVE INTERMITOTIC CELLS

THE ORGANIZATION OF TISSUES AND ORGANS BY THE ABOVE CELLS DETERMINE THEIR RADIO SENSITIVITY

RAPIDLY PROLIFERATING TISSUE, ACUTE TOXICITY




SLOW RENEWAL KINETICS, LATE TOXICITY



SERIAL Vs PARALLEL


◆ Emami et al

◆ Quantec



Functional Sub Unit (FSU) of Critical Organ

Parallel



(a)

Serial



(b)


➤ High dose to small volume is hazardous.

➤ Low dose to large volume may be safe.

Parallel architecture: Liver parenchyma

Liver parenchyma is comprised of discrete polygonal lobules containing hepatocytes and sinusoids flanked by one central vein and multiple portal triads. Each lobule functions independently and thus liver parenchyma is arranged in "parallel." High radiation doses to 10% of the liver parenchyma decreases total liver function minimally, as the remaining 90% continues to function normally.

Other examples of parallel organ architecture include lung alveoli, kidney nephrons, and salivary gland acini.



Serial architecture: Biliary outflow tract

Because of the reliance of biliary system function on adequate outflow at the distal bile duct confluence, high doses to a comparatively small portion of the organ can lead to stricture affecting total organ function.

Other examples of serial organ architecture include spinal cord, esophagus, and urethra.

◆ (TD5/5 AND TD50/5) = 50 Gy & 65 Gy


5% AND 50% OF PATIENTS RISK OF DELAYED GASTRIC TOXICITY IN 5 YEARS HAVE BEEN ESTIMATED AT 50 GY AND 65 GY RESPECTIVELY FOR GASTRIC ULCERATION OR PERFORATION.

(V28 < 20%) ONLY < 5%

IF LESS THAN 20% OF THE KIDNEY VOLUME ARE EXPOSED TO 28 GY (V28 < 20%) ONLY < 5% OF PATIENTS WILL DEVELOP A CLINICALLY RELEVANT KIDNEY DYSFUNCTION


DOSE LIMITATIONS OF OAR IN RADIATION THERAPY FOR UPPER ABDOMINAL MALIGNANCIES

OAR	Dose limitation	End point	Rate (%)
Spinal cord	<ul style="list-style-type: none"> Dmax = 50 Dmax = 60 Dmax = 69 	Myelopathy	<ul style="list-style-type: none"> 0.2 6 50
Whole liver	<ul style="list-style-type: none"> Mean dose 30–32 Mean dose <42 	Classical RILD	<ul style="list-style-type: none"> <5 <50
Small intestine	<ul style="list-style-type: none"> V45 < 195 cc (Entire potential space within peritoneal cavity) 	Grade ≥ 3 acute toxicity	<ul style="list-style-type: none"> <10
Heart	<ul style="list-style-type: none"> Mean dose <26 (Pericardium) V30 < 46% (pericardium) V25 < 10% (whole heart) 	Pericarditis Long-term cardiac mortality	<ul style="list-style-type: none"> <15% <15% <1
Bilateral whole kidneys	<ul style="list-style-type: none"> Mean dose <15–18 Mean dose <28 	Clinically relevant renal dysfunction	<ul style="list-style-type: none"> <5 <50



Kidney, Bilateral	Mean	<15-18Gy	Toxicity Rate <5%	Toxicity Endpoint Clinical Dysfunction
Kidney, Bilateral	Mean	<28Gy	<5%	Clinical Dysfunction
Kidney, Bilateral	V12	<55%	<50%	Clinical Dysfunction
Kidney, Bilateral	V20	<32%	<5%	Clinical Dysfunction
Kidney, Bilateral	V23	<30%	<5%	Clinical Dysfunction
Kidney, Bilateral	V28	<20%	<5%	Clinical Dysfunction

liver, right kidney, left adrenal gland, rib





AVAILABLE DOSE CONSTRAINTS & PROBABLE EFFECTS OF DOSES ON CONCERNED ORGANS

QUANTEC




Fig. 1. Graphic representation of the Baglan–Robertson threshold model for risk of acute small bowel toxicity. Here, “low risk” implies ~10% and “high risk” ~40%. Note that the y-axis represents the absolute volume of individual bowel loops and not the peritoneal space.

V15 = 120 cc


If individual bowel loops are outlined

or

V45 = 195 cc

If entire peritoneal potential space of bowel is outlined

patients without Grade 3 toxicity, the mean V15 was 127 cc, whereas for patients who had Grade 3 toxicity the mean V15 was 319 cc





Crude method

IMPACT ON TYPE OF TISSUES

IMRT
IGRT
VMAT
SRS, SRT
BRACHY


DOSE PER FRACTION
NO OF FRACTIONS
INTERFRACTION
INTERVAL
TOTAL DOSE

Precise method




Conformal Radiotherapy Helical Tomotherapy Proton Beam Therapy






1. BILE PRODUCTION
2. LIPID METABOLISM,
3. GLYCOMETABOLISM
4. ELIMINATION OF VARIOUS WASTE PRODUCTS
5. IMMUNITY
6. AND PLASMA PROTEIN SYNTHESIS




CANAL OF HERING:-CONTAINS OVAL CELL;-STEM CELL

ITO CELL-STELLATE CELL-FIBROSIS



1. **PRODN OF TNF ALFA BY KUFFER CELL**
2. **HEPATOCYTE:- SENESENSE**
3. **SINUSOIDAL ENDOTHELIAL CELL ACTIVATION & APOPTOSIS**
4. **STELLATE CELL ACTIVATION & EMT AND PRODUCTION OF TGF BETA.**
5. **PERIVENULAR FIBROSIS**
6. **OBSTRUCTION OF BILE CANALICULI**
7. **SINUSOIDAL OBSTRUCTION**




CLASSIC		NON CLASSIC
<ul style="list-style-type: none"> ➤ FATIGUE, ABDOMINAL PAIN, INCREASED ABDOMINAL GIRTH, HEPATOMEGALY ➤ ANICTERIC ➤ ASCITES 1–3 MONTHS AFTER LIVER RT. 	CLINICAL FEATURE	<ul style="list-style-type: none"> ➤ MORE DYSREGULATED HEPATIC FUNCTIONS WITH JAUNDICE
<ul style="list-style-type: none"> ➤ ALKALINE PHOSPHATASE (ALP) TRANSAMINASE AND BILIRUBIN :- N 	BIOCHEMICAL	<ul style="list-style-type: none"> ➤ TRANSAMINASES:- FIVEFOLD INCREASE
<ul style="list-style-type: none"> ➤ OBLITERATION OF THE CENTRAL VEIN ➤ DEATH OF CENTRIOLOBULAR HEPATOCYTES ➤ HSC ACTIVATION CONTRIBUTING TO HEPATIC FIBROSIS 	PATHOLOGY	<ul style="list-style-type: none"> ➤ HEPATOCELLULAR LOSS, HEPATIC DYSFUNCTION, HEPATIC SINUSOIDAL ENDOTHELIAL DEATH ➤ HSC ACTIVATION



AMONG THE PATIENTS RECEIVING HEPATIC RADIATION OF 30–35 GY, ~6–66% OF PATIENTS PRESENT SIGNIFICANT RILD. 9, 4–8 WEEKS AFTER TERMINATION OF RT, IT HAS BEEN REPORTED TO APPEAR AS EARLY AS 2 WEEKS OR AS LATE AS 7 MONTHS AFTER RT.

ionizing radiation

radiation nephropathy



1. LOSS OF ENDOTHELIAL CELLS
2. SUB ENDOTHELIAL EXPANSION
3. OCCLUDED CAPILLARY LOOP
4. MESANGIOLYSIS




1. GLOMERULOSCLEROSIS
2. RENAL INTERSTITIAL FIBROSIS
3. TUBULAR ATROPHY

CLINICAL STAGES OF RADIATION NEPHROPATHY


TYPE	TIME AFTER RADIOTHERAPY	TYPE SYMPTOMS

PATHOLOGY	MECHANISM	DRUG	MECHANISM



RADIATION-INDUCED GASTRIC INJURY

PARALLEL ORGAN'.



Radiation risk factors

Total gastric dose, >45 Gy

% Total gastric volume receiving ≥ 50 Gy (V50), $> 16\%$

% Total gastric volume receiving ≥ 25 Gy (V25), $> 6.3\%$

Irradiation of gastric antrum

Combined chemotherapy

Host risk factors


Main portal vein tumor thrombosis

Cirrhosis and portal hypertension


History of upper gastrointestinal bleeding

NO SYMPTOMS/ABDOMINAL PAIN,
ABDOMINAL DISTENSION
HEMATEMESIS

- GASTROSCOPY:- IRRADIATED AREA SHOWS PUNCTATE ULCER. FUSION OF RED PLAQUES, FLATTENING OF FOLDS, ANNULAR ULCERS AND TELANGIECTASIA
- BARIUM MEAL
- CT SCAN:- THICKENING OF THE GASTRIC WALL AND NARROWING OF THE GASTRIC CAVITY
- SERUM GASTRITIS MARKERS (GASTRIN 17, PEPSINOGEN I AND II.




1. ATROPHY OF EPITHELIAL CELLS
2. DEGENERATION OF PARIETAL CELLS AND CHIEF CELLS
3. SUBMUCOSAL EDEMA
4. INFLAMMATION IN THE LAMINA PROPRIA



TREATMENT

- ◆ **OMEPRAZOLE, PANTOPRAZOLE, ESOMEPRAZOLE, LANSOPRAZOLE AND RABEPRAZOLE :-**
 - ◆ **INHIBITION OF GASTRIC ACID.**
 - ◆ **REDUCING NEUTROPHIL AGGREGATION**
 - ◆ **PERMEABILITY OF MAST CELL**
 - ◆ **REDUCING INFLAMMATORY CYTOKINE RELEASE**
 - ◆ **REGULATING OXIDATIVE STRESS BY SCAVENGING ROS AND FREE RADICALS**
- ◆ **VITAMIN A, VITAMIN C AND VITAMIN E ARE NATURAL ANTIOXIDANTS**
- ◆ **ARGON PLASMA COAGULATION (APC) IS A ROUTINE METHOD FOR ENDOSCOPIC TREATMENT OF HEMORRHAGIC GASTRITIS**
- ◆ **MESENCHYMAL STEM CELLS (MSCS) THERAPY**
 - ◆ **POTENTIAL TO DIFFERENTIATE INTO A VARIETY OF CELLS, BUT ALSO HAVE THE ABILITY TO SECRETE CYTOKINES AND MIGRATE TO DAMAGED TISSUES**

**SMALL INTESTINE:-
DUODENUM, JEJUNUM, ILLIUM**



Cell Type	Category	Estimated Percentage of Population of IECs	Functions	Life Span
Enterocytes [9,15,17,40,46,58,63]	Non-secretory	±80%	Sampling of nutrients. Digestion of nutrients. Absorption of nutrients. Maintenance of structural integrity. Surveillance and control gut microbiota. Replacement of damaged Lgr5 ⁺ ISCs.	3–5 days
Goblet cells [8,15,17,22,40,41,68,69]	Secretory	±10%	Sampling of gut microbiota. Sampling of nutrients. Secretion of mucus. Pooling of antimicrobial peptides. Secretion of trefoil factor. Regeneration and repair of epithelium. Replacement of damaged Lgr5 ⁺ ISCs.	3–5 days
Paneth cells [2,14,17,29,30,40,54,75,76,77,78,79,80]	Secretory	±5%	Control of gut microbiota. Sampling of nutrients. Protection of Lgr5 ⁺ ISCs. Nourishment of Lgr5 ⁺ ISCs. Regulation of proliferation and differentiation of Lgr5 ⁺ ISCs. Replacement of damaged Lgr5 ⁺ ISCs.	3–7 weeks
Enteroendocrine cell [40,48]	Secretory	±1%	Sampling of nutrients. Secretion of gut hormones.	3–5 days
Tuft cells [64]	Non-secretory	<1%	Sampling of nutrients. Sampling of gut microbiota. Regulation of gut microbiota. Production of cytokines.	3–5 days

Digestion and absorption

Enterocytes

Tuft cell

IMMUNOREGULATORY CELLS PRODUCES IL-25, ACh, TSLP, β -endorphins, PGE_2 , PGD_2 and LTC_4 ,

SECRETS MUC2, MUC3 AND FORMS A CARPET
ALLOW NUTRIENTS NOT BACTERIA

leucine-rich repeat-containing G-protein-coupled receptor 5
ISCs (Lgr5+ ISCs). The Lgr5+ ISCs in a normal small
intestine are found intermingled with the Paneth cells in a
1:1 ratio

Lgr5+ ISCs

Symmetric division :- clonal expansion
asymmetrical division leads
enterocytes, goblet cells,
enteroendocrine cells,

Goblet cell

Endocrine cell

Crypt

Endothelial cell

Dendritic cell

Lgr5 ISC

Highly sensitive to radiation


Paneth cells

Can De Differentiate

Muscle cell


base of the intestinal crypts, in direct contact with the Lgr5+ ISCs. influence the proliferation and differentiation of the Lgr5+ ISC. Paneth cells contain an abundance of antimicrobial peptides and immunomodulating proteins that


RADIATION ENTEROPATHY/RADIATION ENTERITIS



RISK FACTORS OF RE INCLUDE

1. AGE ABOVE 60 YEARS
2. SMOKING
3. DIABETES MELLITUS
4. HYPERTENSION
5. CONNECTIVE TISSUE DISORDERS
6. HIV STATUS,
7. PREVIOUS ABDOMINAL SURGERY, HYPO-ALBUMINEMIA
8. CONCURRENT ADMINISTRATION OF CHEMOTHERAPY WITH RADIOTHERAPY






1. IONIZING RADIATION MOSTLY AFFECT THE LABILE CELLS SUCH AS THE LGR5+
2. HIGHER DOSE CAN AFFECT STABLE AND PERMANENT CELLS SUCH AS NERVE CELLS, VASCULAR ENDOTHELIAL CELLS AND MUSCLE CELLS
3. SLOUGHING-OFF OF THE EPITHELIAL CELLS AND/OR THEIR VILLI
4. BLEEDING AND PERFORATION
5. DAMAGE TO THE EPITHELIUM OF THE SMALL INTESTINE MAY ALSO LEAD TO DYSBIOSIS
6. LATE COMPLICATION:-
 STEATORRHEA, SHORT BOWEL SYNDROME, MALABSORPTION SYNDROME, BOWEL OBSTRUCTION, INTERNAL AND EXTERNAL FISTULAE, HEPATIC DYSFUNCTION, SECONDARY MALIGNANCIES

TREATMENT OF SMALL BOWEL COMPLICATIONS

- ANALGESICS
- DIETARY MODIFICATION AND ANTI-DIARRHEAL DRUGS
- TOTAL PARENTERAL NUTRITION
- BLEEDING AND SMALL BOWEL OBSTRUCTION (STRICTURES, ADHESIONS, OR RECURRENT TUMOR):-RESECTION AND ANASTOMOSIS
- CREATION OF BYPASS OR BRINGING OUT OF STOMA
- BLEEDING :-TREATED CONSERVATIVELY, ENDOSCOPICALLY :- ARGON BEAM PLASMA COAGULATION AND RADIOFREQUENCY ABLATION, OR SURGICALLY
- STEROIDS, GLUTAMINE, ARGININE, STATINS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, ANTIOXIDANTS, HYPERBARIC OXYGEN, AND HERBAL MEDICATIONS REMAIN EXPERIMENTAL
- MESENCHYMAL STEM CELLS AND RECOMBINANT NICHE FACTORS FOR THE LGR5+ ISCS




PANCREAS

❖ **PANCREATIC ACINAR CELLS ARE KNOWN TO BE RADIORESISTANT.**

❖ **WITH LARGER DOSES OF RADIATION AND TECHNIQUES LIKE IMRT TEND TO SPARE A SIGNIFICANT VOLUME OF THIS CRITICAL ORGAN.**

The latency periods:- early within one year for exocrine function, and very late for endocrine function

ACINAR INJURY
INFLAMMATORY CELLS ARE ABUNDANT AND THE NUMBER OF SECRETORY GRANULES IS REDUCED AND THE CYTOPLASM IS VACUOLATED




ZONAL NECROSIS AND DUCTULE DEGENERATION
LARGE DUCT MILD CELL CHANGES
SMALL DUCTS DISTENDED LUMEN AND PLUGGING BY CELLULAR DEBRIS, ACUTE INJURY TO ARTERIOLES AND VENULES

	Focal	Global
Subclinical	Regional imaging abnormalities; e.g., calcifications on planar images, hyperenhancement on CT, or biliary duct abnormalities on retrograde cholangiopancreatography	Latent diabetes mellitus, glucose intolerance, malabsorption of proteins and fats, reduced levels of pancreatic enzymes in small intestine, or abnormalities in urinary bentiromide
Clinical	Cancer induction	Diabetes mellitus, steatorrhea

PANCREAS:

- ❖ RISK OF DIABETES DUE TO LOSS OF INSULIN, C-PEPTIDE I.E ENDOCRINE AND EXOCRINE LIPASE AND ALPHA AMYLASE DEFICIENCY.
- ❖ A STUDY BY JERZY WYDMANSKI EVALUATED RADIATION INDUCED INJURY OF THE EXOCRINE PANCREAS AMONG 127 GASTRIC CANCER PATIENTS WITH TOTAL DOSE OF 45GY IN 25 FRACTIONS SHOWED LIPASE AND ALPHA AMYLASE DEFICIENCIES IN 48.2% AND 19.7% PATIENTS RESPECTIVELY.





Gastric cancer

Risk of endocrine pancreatic insufficiency in patients receiving adjuvant chemoradiation for resected gastric cancer^{a,b}Cengiz Gemici^{a,*}, Mehmet Sarıoğlu^b, Resat Dabak^b, Mihriban Koca^aDepartment of Oncology; ^bDepartment of Endocrinology
Moltepe University Medical Faculty, Turkey

Conclusion

Abdominal radiotherapy leads to a decrease in beta cell function which may lead to possible diabetogenic effect years later. Radiation-induced pancreatic injury and late effects of radiation on normal pancreatic tissue are unknown and not investigated extensively. Late radiation related pancreatic toxicity is a new concept and should be considered in radiation treatment and radiation toxicity reports.

THE STUDY
DECLINE IN
ADJUVANT


Comparison of the study group (radiotherapy +) and control group (radiotherapy –) according to endocrine functions of the pancreas at initial, 6 and 12 months of the study.

	Study group Radiotherapy (+)	Control group Radiotherapy (–)	p
FBG (mg/dl)			
Initial	92.54 ± 12.2	95.12 ± 22.3	NS
6 months	90.62 ± 12.4	95.19 ± 11.3	NS
12 months	88.46 ± 10.5	90.56 ± 18.0	NS
p	NS	NS	
		89 ± 0.7	NS
		89 ± 0.7	NS
		15 ± 0.5	NS
		25 ± 5.8	NS
		51 ± 6.0	0.05
		47 ± 12.0	0.001
		65 ± 1.2	NS
		40 ± 1.5	0.05
		62 ± 1.9	0.007
HOMA-β			
Initial	85.73 ± 38.4	84.90 ± 32.1	NS
6 months	73.26 ± 28.5	82.49 ± 41.5	0.005
12 months	71.37 ± 24.3	81.49 ± 61.3	0.002
p	0.02	NS	


PRESERVATION OF ENDOCRINE FUNCTION :- MEAN RADIATION DOSE SHOULD BE KEPT BELOW 25 GY.

EARLY ENZYME SUBSTITUTION FOR EXOCRINE PANCREATIC INSUFFICIENCY, AND DIET AND LIFE STYLE CHANGES FOR PREVENTION OF FUTURE DIABETES RISK.


MECHANISM OF SKIN FIBROSIS




NORMAL




INSULT



INJURY RESPONSE MECHANISMS



ABBERANT HEALING/FIBROSIS



THERAPEUTIC STRATEGY TO INHIBIT RADIATION TOXICITY


CAUSATIVE FACTORS	MECHANISM	DRUGS
INFLAMMATORY MEDIATORS	INFLAMMATION VASCULAR MEDIATED INFLAMMATION INTESTINAL CRYPT CELL	CELOCOXIB PENTOXYPHYLLIN VITAMIN E
TGF-BETA TGF –BETA RECEPTOR	FIBROSIS	HALOFUGINONE LY-364947
TNF-ALFA	MACROPHASE	ETANERCEPT
ROS CLEARANCE		ALFA TOCOFEROL, ASCORBIC ACID
ENDOTHELIAL INJURY		STATIN
ANGIOTENSIN II	PRO INFLAMMATORY PRO FIBROGENIC	CAPTOPRIL
STEM CELL MOBILIZER	PROGENITOR CELL DAMAGE	G-CSF PLERIXAFOR

TAKE HOME MESSAGE

PREVENTION IS BETTER THAN CURE

- Proper selection of cases
- Understanding the radiobiology of organ concerned
- Proper dose fractionation schedule
- OAR Constraints
- Stringent Plan evaluation
- Strict IGRT Matching to be ensured
- Proper dosimetry
- Understanding the toxicity and its proper management

PRINCIPLES

- EFFICACY \propto DOSE TO THE TUMOR
- 
- DOSE TO NORMAL STRUCTURES
- DOSE= DAMAGE TO SERIAL ORGAN > PARALLEL ORGAN
- PROLIFERATING CELL MORE AFFECTED THAN PARENCHYMAL CELL
- TOXICITY INVERSELY RELATED TO FUNCTIONAL UNIT

